Interpace Biosciences Inc (IDXG) fair value: what the stock is really worth
As of Sep 3, 2026: fair value of Interpace Biosciences Inc $3.30, price $6.51, upside -49.3%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Interpace Biosciences Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $1.53 – $52.25 · fair‑value band $2.26 – $4.17 · the $6.51 price screens above the $3.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Interpace Biosciences in your weekly email
Every Wednesday you see whether Interpace Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
Show more
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Stock analysis
Interpace Biosciences Inc (IDXG) currently trades at $6.51, while our model-based Fair Value estimate is $3.30, implying the stock looks roughly 97.3% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $16.51 per share, and 7 of the 24 models we run sit above the $6.51 price.
Bear case: the Asset-Based group reads lowest at $0.5400, and 17 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $2.26 (bear) to $4.17 (bull), the price of $6.51 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Interpace Biosciences Inc reported revenue of $38.7M in FY2025 versus $41.3M in FY2021, a compound −1.6%/yr. Reported net income was $24.6M in FY2025.
Key figures
Market cap $46.2M · P/E ratio 1.9 · P/S ratio 1.22 · EPS (TTM) $0.8700 · Net margin 63.5% · Return on equity 214% · Return on assets (EBIT) 8.5% · Operating margin 12.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 43% below its 52-week high and 327% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −49%, IDXG screens richer than that median.
Fair Value models
Bear $2.26Fair Value $3.30Bull $4.17
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.6388 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.54/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−17.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
Start year 2020 (pandemic). Over 10 years: +15.2% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−80.5% (2020) → 10.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: rate outside our plausibility band
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−13.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −15.3% a year for the price.
Compare Interpace Biosciences Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Above median
Fair Value upside−49% · Below median
Profitability
Return on equity (TTM)214% · Top 25%
Return on assets11% · Top 25%
Net margin (TTM)65% · Top 25%
Operating margin (TTM)12% · Above median
Growth and dividend
Revenue growth−22% · Bottom 25%
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (TTM)1.9× · Cheapest 25%
P/B2.06× · Pricier than median
P/S (TTM)1.27× · Cheaper than median
P/FCF8.4× · Pricier than median
EV/EBITDA10.6× · Cheaper than median
PEG0.36× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 28
PAST (return on equity)100· sector 8
HEALTH (low debt)91· sector 95
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Interpace Biosciences Inc (IDXG) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $3.30 versus the last price from Sep 3, 2026 of $6.51, about −49% upside (overvalued).
What is the fair value of IDXG?
Our model-based fair value for Interpace Biosciences Inc is $3.30 (as of Sep 23, 2026), built from audited fundamentals. Last price (from Sep 3, 2026): $6.51.
What is the quality score of IDXG?
Interpace Biosciences Inc has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Interpace Biosciences Inc (IDXG)?
Our model-based price target is the fair value of $3.30 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $2.26, optimistic scenario $4.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Interpace Biosciences Inc stock forecast for 2026?
Our models put fair value at $3.30, about −49% upside versus the last price from Sep 3, 2026 of $6.51 (overvalued). Cautious scenario $2.26, optimistic scenario $4.17. The calculation is refreshed regularly with new filings.
What is the revenue of Interpace Biosciences Inc (IDXG)?
Interpace Biosciences Inc reported trailing-twelve-month revenue of about $36.2M (latest available figure, as of Sep 23, 2026).
What growth is priced into Interpace Biosciences Inc (IDXG)?
For today's price to be fair in a discounted-cash-flow model, Interpace Biosciences Inc would have to grow free cash flow by -13.3 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.6 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of IDXG use?
Our models discount Interpace Biosciences Inc at 8.9 %: a base by market capitalisation (nano), damped by beta 0.65, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Interpace Biosciences Inc that is -13.3 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Interpace Biosciences Inc (IDXG) delivered so far?
Over the past 5 years revenue at Interpace Biosciences Inc grew +3.6 % a year. The price currently implies -13.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Interpace Biosciences Inc (IDXG) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Interpace Biosciences Inc (-13.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Interpace Biosciences Inc (IDXG)?
The free-cash-flow yield on the price is 18.99 %: that much free cash flow Interpace Biosciences Inc produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Interpace Biosciences Inc (IDXG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Interpace Biosciences Inc it is $3.30 per share (as of Sep 23, 2026), against a price of $6.51. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Interpace Biosciences Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, IDXG trades above its calculated fair value: price $6.51, fair value $3.30, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IDXG?
No. The price is what the market pays today ($6.51); the fair value is what the company's own numbers justify ($3.30). For Interpace Biosciences Inc the two are $3.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is Interpace Biosciences Inc worth?
The market values Interpace Biosciences Inc at about $46.2M (market capitalisation, as of Sep 23, 2026). Per share that is $6.51; our models calculate a fair value of $3.30 per share.
What do the bullish and bearish scenarios say about IDXG?
Our models span a range for Interpace Biosciences Inc: cautious scenario $2.26, base $3.30, optimistic $4.17 per share (as of Sep 23, 2026, price $6.51). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IDXG?
Interpace Biosciences Inc trades at a price-to-earnings ratio of 1.9 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.30 is built from several models across several years. Other multiples: PEG 0.4, P/B 2.1, P/S 1.3, EV/EBITDA 10.6.
What is the PEG ratio of IDXG?
The PEG ratio of Interpace Biosciences Inc is 0.36 (P/E divided by earnings growth, as of Sep 23, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Interpace Biosciences Inc (IDXG)?
Balance-sheet figures for Interpace Biosciences Inc (as of Sep 23, 2026): return on equity 213.9%, debt of 0.19 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is IDXG from its 52-week high?
Interpace Biosciences Inc trades at $6.51, about 43% below its 52-week high of $11.50 and 327% above the low of $1.53 (as of Sep 3, 2026). Distance from the high says nothing about value: that is what the fair value of $3.30 is for.
Which stocks are comparable to Interpace Biosciences Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Interpace Biosciences Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $6.51, calculated fair value $3.30 (−49%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IDXG calculated?
We run Interpace Biosciences Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.30, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Interpace Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Interpace Biosciences Inc (IDXG)?
The latest price we hold is from Sep 3, 2026 and stands at $6.51. Our model-based fair value is $3.30, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Interpace Biosciences Inc right now?
The price sits above even our optimistic bull case ($4.17). The favourable scenario is already priced in. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($2.26 to $4.17) leaves room in how you read the outcome.
Key figures of Interpace Biosciences Inc
How large is the market capitalisation of Interpace Biosciences Inc (IDXG)?
The market capitalisation of Interpace Biosciences Inc is $46.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Interpace Biosciences Inc (IDXG)?
The price-to-sales ratio of Interpace Biosciences Inc is 1.22 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Interpace Biosciences Inc (IDXG)?
Earnings per share at Interpace Biosciences Inc are $0.8700 (price ÷ EPS = P/E 1.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Interpace Biosciences Inc (IDXG)?
The net margin of Interpace Biosciences Inc is 63.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Interpace Biosciences Inc (IDXG)?
The return on equity (ROE) of Interpace Biosciences Inc is 214% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Interpace Biosciences Inc (IDXG)?
On an EBIT basis the return on assets of Interpace Biosciences Inc is 8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Interpace Biosciences Inc (IDXG)?
The operating margin of Interpace Biosciences Inc is 12.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Interpace Biosciences Inc (IDXG)?
Revenue at Interpace Biosciences Inc is growing −21.6% versus a year earlier (3y avg +6.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Interpace Biosciences Inc (IDXG)?
Earnings per share at Interpace Biosciences Inc are growing −53.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Interpace Biosciences Inc (IDXG) carry?
The net debt of Interpace Biosciences Inc is $2.8M (fiscal year 2024, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Interpace Biosciences Inc in the live analysis
One click puts Interpace Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 23, 2026